Dr. Shahda on BBI-608 With Gemcitabine and Nab-Paclitaxel in Patients with mPDAC
Safi Shahda, MD, assistant professor of Clinical Medicine, Indiana University School of Medicine, discusses a phase Ib study examining the cancer stem cell pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
Safi Shahda, MD, assistant professor of Clinical Medicine, Indiana University School of Medicine, discusses a phase Ib study examining the cancer stem cell pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
In the open-label, multicenter study, 31 patients received BBI-608 at 240 mg twice daily (BID) in combination with gemcitabine at 125 mg/m2 and nab-paclitaxel at 1000 mg/m2 weekly for 3 out every 4 weeks.
The most common adverse events that were reported included grade 1 diarrhea, abdominal pain, nausea, and fatigue. There was one case of grade 3 dehydration, which was managed. Additionally, no dose-limiting toxicities were observed, suggesting that this regimen is well-tolerated for these patients.
<<<
